© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 10, 847-853,
May 19, 1999
© 1999 Oxford University Press
Incremental Costs of Enrolling Cancer Patients in Clinical Trials: a Population-Based Study
Affiliations of authors: J. L. Wagner, Congressional Budget Office, Washington, DC; S. R. Alberts, J. A. Sloan, S. Cha, J. Killian, M. J. O'Connell, P. Van Grevenhof, C. G. Chute, Mayo Clinic, Rochester, MN; J. Lindman, Western Michigan University, Kalamazoo, MI.
Correspondence to: Steven R. Alberts, M.D., M.P.H., Division of Medical Oncology, Mayo Clinic, 200 First St., SW, Rochester, MN 55905.
BACKGROUND: Payment for care provided as part of clinical research has become less predictable as a result of managed care. Because little is known at present about how entry into cancer trials affects the cost of care for cancer patients, we conducted a matched case-control comparison of the incremental medical costs attributable to participation in cancer treatment trials. METHODS: Case patients were residents of Olmsted County, MN, who entered phase II or phase III cancer treatment trials at the Mayo Clinic from 1988 through 1994. Control patients were patients who did not enter trials but who were eligible on the basis of tumor registry matching and medical record review. Sixty-one matched pairs were followed for up to 5 years after the date of trial entry for case patients or from an equivalent date for control patients. Hospital, physician, and ancillary service costs were estimated from a population-based cost database developed at the Mayo Clinic. RESULTS: Trial enrollees incurred modestly (no more than 10%) higher costs over various follow-up periods. The mean cumulative 5-year cost in 1995 inflation-adjusted U.S. dollars among trial enrollees after adjustment for censoring was $46 424 compared with $44 133 for control patients. After 1 year, trial enrollee costs were $24 645 compared with $23 964 for control patients. CONCLUSIONS: This study suggests that cancer chemotherapy trials may not imply budget-breaking costs. Cancer itself is a high-cost illness. Clinical protocols may add relatively little to that cost.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. D. Ramsey, S. D. Sullivan, and R. M. Kaplan Cost-Effectiveness of Lung Volume Reduction Surgery Proceedings of the ATS, May 1, 2008; 5(4): 406 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Hillner Barriers to Clinical Trial Enrollment: Are State Mandates the Solution? J Natl Cancer Inst, July 21, 2004; 96(14): 1048 - 1049. [Full Text] [PDF]
|
|
|
|
|
|
C. P. Gross, V. Murthy, Y. Li, A. D. Kaluzny, and H. M. Krumholz Cancer Trial Enrollment After State-Mandated Reimbursement J Natl Cancer Inst, July 21, 2004; 96(14): 1063 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Sherman, D. M. Rubin, E. Venkatraman, G. K. Schwartz, V. A. Miller, M. H. Radzyner, H. S. Ruchlin, D. Spriggs, and D. G. Pfister Using Patients As Their Own Controls for Cost Evaluation of Phase I Clinical Trials J. Clin. Oncol., April 1, 2004; 22(7): 1308 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bailey and C. Urquhart Information Needs in a Clinical Trials Unit Health Informatics Journal, June 1, 2003; 9(2): 111 - 126. [Abstract] [PDF]
|
|
|
|
 |
|
 National Emphysema Treatment Trial Research Group Cost Effectiveness of Lung-Volume-Reduction Surgery for Patients with Severe Emphysema N. Engl. J. Med., May 22, 2003; 348(21): 2092 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Pearson, P. A. Ganz, K. McGuigan, J. R. Malin, J. Adams, and K. L. Kahn The Case Identification Challenge in Measuring Quality of Cancer Care J. Clin. Oncol., November 1, 2002; 20(21): 4353 - 4360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Ramsey, C. M. Moinpour, L. C. Lovato, J. J. Crowley, P. Grevstad, C. A. Presant, S. E. Rivkin, K. Kelly, and D. R. Gandara Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, February 20, 2002; 94(4): 291 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Roche, N. Paul, B. Smuck, M. Whitehead, B. Zee, J. Pater, M.-A. Hiatt, and H. Walker Factors Affecting Workload of Cancer Clinical Trials: Results of a Multicenter Study of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., January 15, 2002; 20(2): 545 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Bennett, J. R. Adams, K. S. Knox, A. M. Kelahan, S. M. Silver, and J. S. Bailes Clinical Trials: Are They a Good Buy? J. Clin. Oncol., December 1, 2001; 19(23): 4330 - 4339. [Abstract] [Full Text]
|
|
|
|
 |
|
 S.-Y. Sun, P. Yue, G. J. Kelloff, V. E. Steele, S. M. Lippman, W. K. Hong, and R. Lotan Identification of Retinamides That Are More Potent than N-(4-Hydroxyphenyl)retinamide in Inhibiting Growth and Inducing Apoptosis of Human Head and Neck and Lung Cancer Cells Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 595 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Leibson, S. K. Katusic, W. J. Barbaresi, J. Ransom, and P. C. O'Brien Use and Costs of Medical Care for Children and Adolescents With and Without Attention-Deficit/Hyperactivity Disorder JAMA, January 3, 2001; 285(1): 60 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Goldman, M. L. Schoenbaum, A. L. Potosky, J. C. Weeks, S. H. Berry, J. J. Escarce, B. A. Weidmer, M. L. Kilgore, N. Wagle, J. L. Adams, et al. Measuring the Incremental Cost of Clinical Cancer Research J. Clin. Oncol., January 1, 2001; 19(1): 105 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Presant Patient Costs on Clinical Trials J Natl Cancer Inst, September 6, 2000; 92(17): 1441 - 1442. [Full Text] [PDF]
|
|
|
|
|
|
C. L. Bennett, T. J. Stinson, V. Vogel, L. Robertson, D. Leedy, P. O'Brien, J. Hobbs, T. Sutton, J. C. Ruckdeschel, T. N. Chirikos, et al. Evaluating the Financial Impact of Clinical Trials in Oncology: Results From a Pilot Study From the Association of American Cancer Institutes/Northwestern University Clinical Trials Costs and Charges Project J. Clin. Oncol., August 15, 2000; 18(15): 2805 - 2810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Fireman, L. Fehrenbacher, E. P. Gruskin, and G. T. Ray Cost of Care for Patients in Cancer Clinical Trials J Natl Cancer Inst, January 19, 2000; 92(2): 136 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Brown Cancer Patient Care in Clinical Trials Sponsored by the National Cancer Institute: What Does It Cost? J Natl Cancer Inst, May 19, 1999; 91(10): 818 - 819. [Full Text] [PDF]
|
|